Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients
NCT ID: NCT03011177
Last Updated: 2019-02-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
168 participants
INTERVENTIONAL
2017-01-31
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study to Evaluate the Efficacy and Safety of Teneligliptin
NCT03793023
Tenelia Triple Combination Study
NCT02567994
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
NCT00954447
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
NCT01214239
Linagliptin Add-on to Insulin Background Therapy
NCT02897349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
teneligliptin
teneligliptin 20mg qd
Teneligliptin
teneligliptin 20mg qd
linagliptin
linagliptin 5mg qd
Linagliptin
linagliptin 5mg qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Teneligliptin
teneligliptin 20mg qd
Linagliptin
linagliptin 5mg qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with type 2 diabetes mellitus
* Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit
* Patients with Fasting Plasma Glucose \<15mmol/L(270mg/dL) on screening
Exclusion Criteria
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Handok Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP_C402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.